Trending...
- Investigation Into North Spokane Shooting That Left Two Dead Continues
- City of Tacoma Invites Community Input on Proposals to Modernize Housing, Zoning, and Land Use Codes for 2026
- Blasting Off with Space Sector Companies: Artemis II Manned Moon Mission is Set to Launch: Could $ASTI be on the Same Rocket Ride as $ASTS & $LUNR?
STUART, Fla., April 19, 2024 ~ Stuart Therapeutics, Inc., a clinical-stage ophthalmic biopharmaceutical company, is making strides in the development of therapies for various eye disorders. The company's President and CEO, Eric Schlumpf, will be presenting their latest research results at two upcoming meetings in early May.
On Friday, May 3rd, Schlumpf will be speaking at the Dry Horizons Symposium, co-sponsored by Ora, Inc. His presentation will focus on Stuart Therapeutics' innovative dry eye disease program, which is currently in a Phase 3 trial. The following day, Saturday May 4th, he will be presenting the company's latest pre-clinical results in retinitis pigmentosa and exudative retinal indications at the Ophthalmology Innovation Source (OIS) Retina Meeting.
Both of these meetings will take place at the Four Seasons Hotel in Seattle, Washington. This provides an opportunity for Stuart Therapeutics to showcase their groundbreaking research to a wide audience of industry professionals.
More on Washingtoner
In addition to Schlumpf's presentations, members of Stuart Therapeutics' R&D team have also co-authored a poster presentation that will be presented by researchers from the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting from May 5-9, 2024. The poster presentation titled "Scleral collagen remodeling and repair assessed in intact eyes through Second Harmonic Generation" focuses on work done at the University of Rochester using Stuart Therapeutics' proprietary collagen mimetic peptide platform. This research aims to understand its effectiveness in reversing scleral collagen disruption in the eye, which is believed to contribute to myopia.
The study authors include Aldo Tecse, Kaitlin Wozniak, James German, Alex McMullen, Mark Buckley, Robert Baratta, Eric Schlumpf, Brian J. Del Buono, Michael Telias and Susana Marcos. This collaboration between Stuart Therapeutics and the University of Rochester highlights the company's commitment to advancing the field of ophthalmology and finding new treatments for eye disorders.
Stuart Therapeutics' presence at these upcoming meetings demonstrates their dedication to innovation and their potential to make a significant impact in the field of ophthalmology. With their cutting-edge research and promising results, they are poised to become a leader in developing therapies for anterior segment, refractive, and posterior segment eye disorders.
On Friday, May 3rd, Schlumpf will be speaking at the Dry Horizons Symposium, co-sponsored by Ora, Inc. His presentation will focus on Stuart Therapeutics' innovative dry eye disease program, which is currently in a Phase 3 trial. The following day, Saturday May 4th, he will be presenting the company's latest pre-clinical results in retinitis pigmentosa and exudative retinal indications at the Ophthalmology Innovation Source (OIS) Retina Meeting.
Both of these meetings will take place at the Four Seasons Hotel in Seattle, Washington. This provides an opportunity for Stuart Therapeutics to showcase their groundbreaking research to a wide audience of industry professionals.
More on Washingtoner
- TL International Group Becomes First Global Operator to Fully Migrate to Pulsant's Dedicated Car Rental Cloud
- Diveroli Investment Group Files 13D in PetMed Express, Highlights Strategic Value, Asset Floor, and Multiple Takeover Pathways
- Deep Learning Robotics (DLRob) Announces Pre-Launch of Zero-Teach and Teach-by-Demonstration Technology for Kitting Applications
- The Quasar Dipole Phenomenon is likely just a complex systematics artifact
- The Rise of Comprehensive Home Water Treatment Systems
In addition to Schlumpf's presentations, members of Stuart Therapeutics' R&D team have also co-authored a poster presentation that will be presented by researchers from the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting from May 5-9, 2024. The poster presentation titled "Scleral collagen remodeling and repair assessed in intact eyes through Second Harmonic Generation" focuses on work done at the University of Rochester using Stuart Therapeutics' proprietary collagen mimetic peptide platform. This research aims to understand its effectiveness in reversing scleral collagen disruption in the eye, which is believed to contribute to myopia.
The study authors include Aldo Tecse, Kaitlin Wozniak, James German, Alex McMullen, Mark Buckley, Robert Baratta, Eric Schlumpf, Brian J. Del Buono, Michael Telias and Susana Marcos. This collaboration between Stuart Therapeutics and the University of Rochester highlights the company's commitment to advancing the field of ophthalmology and finding new treatments for eye disorders.
Stuart Therapeutics' presence at these upcoming meetings demonstrates their dedication to innovation and their potential to make a significant impact in the field of ophthalmology. With their cutting-edge research and promising results, they are poised to become a leader in developing therapies for anterior segment, refractive, and posterior segment eye disorders.
0 Comments
Latest on Washingtoner
- Patent Bar Exam Candidates Achieve 30% Higher Pass Rates with Wysebridge's 2026 Platform
- Municipal Carbon Field Guide Launched by LandConnect -- New Revenue Streams for Cities Managing Vacant Land
- Hoy Law Wins Supreme Court Decision Establishing Federal Trucking Regulations as the Standard of Care in South Dakota
- Tacoma City Council Announces City Manager Finalists
- City of Tacoma Observes Presidents Day on February 16
- Dr. Rashad Richey's Indisputable Shatters Records, Over 1 Billion YouTube Views, Top 1% Podcast, 3.2 Million Viewers Daily
- Grand Opening: New Single-Family Homes Now Open for Sale at Heritage at Manalapan
- Spokane: Presidents Day is a Parking Meter Holiday
- Shelter Structures America Announces Distribution Partnership with The DuraTrac Group
- The OpenSSL Corporation Releases Its Annual Report 2025
- Iranian-Born Engineer Mohsen Bahmani Introduces Propeller-Less Propulsion for Urban Air Mobility
- Aleen Inc. (C S E: ALEN.U) Advances Digital Wellness Vision with Streamlined Platform Navigation and Long-Term Growth Strategy
- RimbaMindaAI Officially Launches Version 3.0 Following Strategic Breakthrough in Malaysian Market Analysis
- Fed Rate Pause & Dow 50k: Irfan Zuyrel on Liquidity Shifts, Crypto Volatility, and the ASEAN Opportunity
- 20/20 Institute Launches Updated Vision Correction Procedures Page for Denver & Colorado Springs
- OneVizion Announces Next Phase of Growth as Brad Kitchens Joins Board of Directors
- New Children's Picture Book "Diwa of Mount Luntian" Focuses on Calm, Culture, and Connection for Today's Families
- Actor, Spokesperson Rio Rocket Featured in "Switch to AT&T" Campaign Showing How Customers Can BYOD and Keep Their Number
- The World's No.1 Superstar® Brings Disco Fever Back With New Global Single and Video "Disco Dancing"
- Boston Industrial Solutions' Natron® 512N Series UV LED Ink Achieves BPA Certification, Advancing Safe and Sustainable Digital Printing